About Belite Bio
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- San Diego, California
- Founded
- 2018
- Company type
- Public Company
Belite Bio (NASDAQ: BLTE) is a San Diego based clinical stage drug development company targeting untreatable eye diseases, such as dry AMD and Stargardt disease (STGD1) which is the most common inherited retinal dystrophy, and metabolic diseases. Its lead pipeline, Tinlarebant (aka LBS-008), is a novel oral once-a-day tablet intended to treat Dry AMD and STGD1 early. Tinlarebant is in phase 3 and has been granted Fast Track & RPD designation in the US, and ODD in the US and EMA for STGD1.
Specialties
- RBP4
- Drug Development
- Dry Age-Related Macular Degeneration
- Stargardt Disease
- Diabetes
- NASH
- and NAFLD
Company locations
5820 Oberlin Drive, Suite 101, San Diego, California 92121, US
Locations listed on the company profile. These may include offices outside the United States, and not every location is hiring.
Business areas
- Biotechnology
- Health Care
- Pharmaceutical
On LinkedIn
- Followers
- 5,234
- People linked to this company
- 80
People who list this company on LinkedIn, not a verified employee count. Figures reflect the saved company profile.
Funding raised
588,750,000 USD
Total reported by Crunchbase, in US dollars. This is funding raised, not company revenue or valuation.
Explore the company
Employer category
Other employer
Estimated from the company profile. This category has not been confirmed by the employer.